Fewer than 10% of patients eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the global health agency as it releases its initial advice on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to broad access to the treatments that can assist patients in reducing considerable weight, explains the body.
Even under the present most favorable outlook, the supply of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the WHO.
The guideline calls on nations and manufacturers to increase access, via approaches including patent sharing.
A patent on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026.
The injections replicate a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals consume fewer calories.
Patients commonly begin shedding pounds after several weeks of starting on the once-weekly jabs.
Studies indicates users may put most of the weight back on within a year of discontinuing the drug, because their normal food cravings resume.
Being overweight or obese increases your likelihood for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in countries worldwide and was linked to millions of deaths worldwide in 2024, per the WHO.
Elena Vance is a wellness writer and positivity advocate who shares insights on mindfulness and joyful living.